Uddevalla Hospital
Uddevalla, 45 198, Sweden
Location status: Recruiting
NCT Number: NCT07037589
This prospective multicenter observational study evaluates whether women ≥50 years with isolated acute hemorrhagic cystitis (AHC) and macroscopic hematuria require full malignancy workup. All participants undergo standard diagnostics (cystoscopy, CT urography, cytology), with 12-month follow-up for cancer detection. The aim is to identify low-risk patients where invasive investigations may be safely avoided.
Interested in participating?
Request Info18 year–110 year
Female
Observational
Uddevalla, 45 198, Sweden
Location status: Recruiting
The BLUSH trial is a prospective, multicenter, observational study investigating whether full malignancy workup is necessary in women ≥50 years presenting with isolated acute hemorrhagic cystitis (AHC) and macroscopic hematuria. AHC is defined as macroscopic hematuria accompanied by acute lower urinary tract symptoms (dysuria, frequency, urgency) of less than one week's duration. Women with prior urological malignancies, significant comorbidities, or impaired consent capacity are excluded.
All enrolled patients undergo standardized initial assessment including full clinical history (smoking, family history, comorbidities), physical examination, urinalysis, urine culture, cystoscopy, CT urography, and cytology when indicated. Participants are stratified into AHC and non-AHC groups based on symptomatology and laboratory findings. Data collection includes demographics, symptom duration, urine findings, cancer diagnoses (type, stage, grade), treatment details, and clinical outcomes.
Patients are followed for a minimum of 12 months via medical record review to capture delayed cancer diagnoses. Data are pseudonymized and stored securely under GDPR regulations. The primary outcome is the incidence of urological malignancy within one year. Secondary outcomes include time to diagnosis, proportion of avoidable invasive procedures, and accuracy of the AHC classification in predicting cancer risk.
The study aims to support individualized risk-based management in women with hematuria.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Observational study. All patients in this group undergo standard diagnostic evaluation including cystoscopy, CT urography, and urine cytology (if clinically indicated), performed during initial assessment for acute macroscopic hematuria.
All patients in this group undergo standard diagnostic evaluation including cystoscopy, CT urography, and urine cytology (if clinically indicated), performed during initial assessment for atypical or chronic presentations of macroscopic hematuria.
Time frame: At least 12 months from study inclusion.
The proportion of women diagnosed with urological cancer (bladder, upper urinary tract, or kidney cancer) within 12 months after initial presentation of macroscopic hematuria.
Time frame: At least 12 months from study inclusion.
Duration from initial presentation to confirmed diagnosis of urological malignancy.
Time frame: At least 12 months from study inclusion.
Percentage of invasive diagnostic procedures (e.g., cystoscopy, CT-urography) in the Acute Hemorrhagic Cystitis Group (AHG) that could have been avoided based on study findings.
Time frame: At least 12 months from study inclusion.
Accuracy of the acute hemorrhagic cystitis (AHC) clinical classification in predicting urological malignancy, measured by sensitivity and specificity.
Contact information is provided by the study sponsor or research team.
Vastra Gotaland Region
Other Gov
Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed? A Prospective Multicenter Study. BLUSH Trial
Acronym: BLUSH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07395037
Bladder Cancer, Carcinoma
London, United Kingdom
View Trial DetailsNCT05646485
Behavior, Bladder Cancer
Dallas, Texas, United States
View Trial DetailsNCT06026189
Bladder Cancer, Carcinoma
Rotterdam, Netherlands
View Trial DetailsNCT06469229
Bladder Cancer, Carcinoma
Shanghai, Shanghai Municipality, China
View Trial Details